Abstract:Glioblastoma (GBM), a common malignant brain tumor, is highly resistant to most treatments, largely due to disease heterogeneity and resistance mechanisms. We investigated TG02, a multi-kinase inhibitor with established anti-tumor activities in hematologic malignancies, for a potential GBM therapy. We previously demonstrated that TG02 inhibited CDK9-mediated transcriptional regulation of anti-apoptotic proteins and induced Cytochrome c release, inducing cell apoptosis through Caspase-3 activation. Additionally, TG02 and Temozolomide (TMZ) demonstrated a synergistic anti-glioma effect in vivo and in vitro. A phosphorylation mimic form of CDK9 was overexpressed in GBM cell and cell viability was via cell counting. NADH dehydrogenase activity was measured to determine mitochondrial respiratory chain complex I activity. The glycolytic effects were measured by Seahorse assay and Western blotting of the key enzymes. Mitochondrial membrane potential change and apoptosis were measured by FACS with DiOC6, and Hoechst/PI staining, respectively. Pharmacodynamic studies were carried out using a syngeneic GBM mouse model. We demonstrated that overexpressed phosphorylation mimic form of CDK9 partially blocked TG02-induced cell death, suggesting that CDK9 mediates TG02-induced cytotoxicity. We demonstrated that TG02 caused mitochondrial dysfunction partially by reducing mitochondrial respiratory chain complex I activity. Additionally, TG02 inhibited glycolysis by downregulating key glycolytic regulators, including Hexokinase-2 (HK-2) and Pyruvate kinase M2 (PKM2), leading to ATP depletion. Combined treatment further enhanced ATP depletion, explaining the synergism between TG02 and TMZ. More importantly, TG02 did not cause mitochondrial damage and apoptosis in normal human astrocytes, suggesting a feasible therapeutic window for TG02. Furthermore, our pharmacodynamic studies confirmed that TG02 suppressed CDK9 activity in brain tumor tissues. TG02 has unique anti-glioma effects through transcriptional regulation of survival proteins, and reduction of cellular energy level in GBM cells. Our preclinical results have led to an ongoing Phase I//II clinical trial for patients with refractory GBM (NCT02942264).

Poster Session AP2: Cell Death and Survival

Potential Therapeutic Effects of Thiazolidinedione on Malignant Glioma

PPARγ-independent Antitumor Effects of Thiazolidinediones

Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse

The engagement of Ras/Raf/MEK/ERK and PLCγ1/PKC pathways regulated by TrkB receptor in resistance of glioma cells to elimination upon apoptosis induction

Peroxisome Proliferator-Activated Receptor Gamma Agonist Pioglitazone Inhibits Beta-Catenin-Mediated Glioma Cell Growth And Invasion

EXTH-62. TG02, A NOVEL TARGETING OF TRANSCRIPTION AND METABOLISM IN GLIOBLASTOMA

Role of SIRT1-mediated Mitochondrial and Akt Pathways in Glioblastoma Cell Death Induced by Cotinus Coggygria Flavonoid Nanoliposomes

Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits glioma cell growth mediated by β-catenin

Effect of p53 targeting small molecule RITA combined with temozolomide on the growth of glioma cells in vitro

Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits β-catenin-mediated glioma cell growth and invasion

Combinatorial Therapeutic Effect of Inhibitors of Aldehyde Dehydrogenase and Mitochondrial Complex I, and the Chemotherapeutic Drug, Temozolomide against Glioblastoma Tumorspheres

Pioglitazone Protect PC12 Cells Against Oxidative Stress Injury: Involvement of Anti-apoptotic Effect and PPARγ Activation

Antitumor Effect of 2-Methoxyestradiol in A Rat Orthotopic Brain Tumor Model

Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib

Ccrg-01. Myt1 Blockade As A Novel Glioma Therapeutics Through Abrogatiing Of The G2/M Cell Cycle Checkpoint

Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity

Effects of Pioglitazone on Cell Apoptosis and Free Radical Levels in Brain Tissue of Rats withIntracerebral Hemorrhage

Pioglitazone Modulates the Proliferation and Apoptosis of Vascular Smooth Muscle Cells Via Peroxisome Proliferators-Activated Receptor-Gamma

Dddr-13. Optimizing Brain Cancer Therapy: Balancing Tumor Eradication And Normal Tissue Preservation With Bpm31510

Troglitazone Induced Apoptosis Via PPARγ Activated POX-induced ROS Formation in HT29 Cells.